Opus forms epileptic drug monitoring deal:
This article was originally published in Clinica
Opus Diagnostics has entered into an exclusive licence agreement with Dainippon Pharmaceuticals, whereby Opus will develop a diagnostic test to monitor blood levels of the anti-epileptic drug, Zonisamide. The test is expected to monitor levels of the drug in selected patients in order to help physicians optimise dosage and patient outcomes. Zonisamide, developed by Osaka, Japan-based Dainippon, is licensed in the US and Europe to Elan Pharmaceuticals. Opus, a wholly owned subsidiary of Fort Lee, New Jersey-based Caprius, says it is investigating other opportunities of co-operation with Dainippon in the diagnostics field.